Prophylaxis of Bacterial meningitis

Infectious Disease Clinics of North America

Volumn 13, Issue 3, 1999, Pages 685-710

  Peltola, H ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; CIPROFLOXACIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; MINOCYCLINE; OFLOXACIN; PNEUMOCOCCUS POLYSACCHARIDE; RIFAMPICIN; SULFONAMIDE;

BACTERIAL MENINGITIS; DRUG EFFICACY; DRUG INDICATION; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; INFECTION RISK; NEISSERIA MENINGITIDIS; PROPHYLAXIS; REVIEW; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 0032792026     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70101-X     Document Type: Article

References (140)

1. van Alphen L. L. Spanjaard van der Ende A. Effect of nationwide vaccination of 3-month-old infants in The Netherlands with conjugate Haemophilus influenzae type b vaccine: High efficacy and lack of herd immunity J Pediatr 131 1997 869
2. N.V. Amata E. Finger E.C. Gotschlich Serologic response to serogroup C meningococcal polysaccharide in Brazilian preschool children Rev Inst Med Trop São Paulo 16 1974 149
3. American Academy of Pediatrics Revision of recommendation for use of rifampin prophylaxis of contacts of patients with Haemophilus influenzae infection Pediatrics 74 1984 301
4. American Academy of Pediatrics Meningococcal disease prevention and control strategies for practice-based physicians Pediatrics 97 1996 404
5. E.L. Anderson T. Bowers C.M. Mink Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults Infect Immun 62 1994 3391
6. M.S. Artenstein R. Gold J.G. Zimmerly Prevention of meningococcal meningitis by group C polysaccharide vaccine N Engl J Med 282 1970 417
7. R. Austrian R.M. Douglas G. Schiffman Prevention of pneumococcal pneumonia by vaccination Transactions of the Association of American Phys 89 1976 184
8. J.D. Band D.W. Fraser G. Ajello Prevention of Haemophilus influenzae type b disease JAMA 251 1984 2381
9. E.D. Barnett A.E. Breña E.R. McNamara Response to quadrivalent meningococcal vaccine in children less than 2 years of age [abstract] Pediatr Res 39 part 2 1996 166
10. A. Bartoloni F. Norelli C. Ceccarini Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide Vaccine 13 1995 463
11. N.T. Begg E. Miller G.K. Fairly Antibody responses and symptoms after DTP and either tetanus or diphtheria Haemophilus influenzae type b conjugate vaccines given for primary immunisation by separate or mixed injection Vaccine 13 1995 1547
12. G. Bennett Cockroaches as carriers of bacteria Lancet 341 1993 732
13. G. Bjune E.A. Højby J.K. Grønnesby Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway Lancet 338 1991 1093
14. S.B. Black H.E. Shinefield B. Fireman Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children Pediatr Infect Dis J 10 1991 97
15. Black SB, Shinefield HE, Ray P, et al: Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: Results of the Northern California Kaiser Permanenete Efficacy Trial [abstract LB-9]. In Programs and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 1998, p 23
16. G. Bolan C.V. Broome R.R. Facklam Pneumococcal vaccine efficacy in selected populations in the United States Ann Intern Med 104 1986 1
17. R. Booy S. Hodgson L. Carpenter Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T Lancet 344 1994 362
18. B.L. Brandt M.S. Artenstein Duration of antibody responses after vaccination with group C Neisseria meningitidis polysaccharide J Infect Dis 131 1975 569
19. J.C. Butler R.F. Breiman J.F. Campbell Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations JAMA 270 1993 1826
20. S.J. Ceesay S.J. Allen A. Menon Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization J Infect Dis 167 1993 1212
21. Centers for Disease Control Serogroup B meningococcal disease—Oregon, 1994 MMWR Morb Mortal Wkly Rep 44 1995 121
22. S.L. Cochi D.W. Fleming A.W. Hightower Primary invasive Haemophilus influenzae type b disease: A population-based assessment of risk factors J Pediatr 108 1986 887
23. D. Cohen M. Green C. Block Reduction of transmission of shigellosis by control of houseflies (Musca domestica) Lancet 337 1991 993
24. O.R. Cordeiro C.P. Colls A.A. Fernandez Eficacia poslicenciamiento de VA-MENGOC-BC en menores de 6 años en Holguín, Cuba. Primer año de observación Rev Cubana Med Trop 47 1995 59
25. Costa E de A. On the controversy abut the efficacy of the antimeningococcal B vaccine: Methodological pitfalls Cadernos de Saúde Pública (Rio de Janeiro) 11 1995 332
26. Costa E de A. H. Martins C.H. Klein Avaliação da proteção conferidda pela vacina antimenigocócica BC no Estado de Santa Catarina, Brazil, 1990/92 Rev Saúde Pública 30 1996 460
27. E.A. Costa Effectiveness of meningococcal vaccine in Brazil Int J Epidemiol 26 1997 681
28. R. Dagan D. Englehard E. Piccard Epidemiology of invasive childhood pneumococcal infection in Israel JAMA 268 1992 3328
29. R.R. Dagan M. Melamed L. MUallem Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococal vaccine J Infect Dis 174 1996 1271
30. R. Dagan J. Eskola C. Leclerc Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants Infect Immun 66 1998 2093
31. Debbag R, Rüttimann R, Stamboulian D: Evaluation of adverse reactions associated to antimeningococcal BC vaccination in 16,700 children [abstract 420]. In Programs and Abstracts of the 33th Annual Meeting of the Infectious Diseases Society of America, San Francisco, 1997, p 790
32. De Moraes J.C. B.A. Perkins M.C.C. Camargo Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil Lancet 340 1992 1074
33. De Wals P. L. Hertoghe I. Borlee-Grime Meningococcal disease in Belgium. Secondary attack-rate among household, day-care nursery and pre-elementary school contacts J Infect Dis 3 suppl 1981 53
34. De Wals P. M. Dionne M. Douville-Fradet Impact of a mass immunization campaign against serogroup C meningococcus in the province of Quebec, Canada Bull World Health Organ 74 1996 407
35. G. Echániz-Aviles N. Carnalla-Barajas M.E. Velásquez-Meza Capsular types of Streptococcus pneumoniae causing disease in children from Mexico City Pediatr Infect Dis J 14 1995 907
36. H.H. Erwa M.A. Haseeb A.A. Idris A serogroup A meningococcal polysaccharide vaccine Bull World Health Organ 49 1973 301
37. J. Eskola A. Takala H. Käyhty Secondary cases of invasive disease caused by spread of Haemophilus influenzae type b J Infect 14 1987 233
38. J. Eskola A.K. Takala E. Kela Epidemiology of invasive preumococcal infections in children in Finland JAMA 268 1992 3323
39. J. Eskola H. Käyhty A.K. Takala A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease N Engl J Med 323 1990 1381
40. Eskola J. Ölander R.-M. T. Hovi Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine Lancet 348 1997 1688
41. C.K. Fairley N. Begg R. Borrow Conjugate meningococcal serogroup A and C vaccine: Reactogenicity and immunogenicity in United Kingdom infants J Infect Dis 174 1996 1360
42. R.D. Feigin C.J. Baker L.A. Herwaldt Epidemic meningococcal disease in an elementary-school classroom N Engl J Med 307 1982 1255
43. D.S. Fedson E.D. Shapiro F.M. LaForce Pneumococcal vaccine after 15 years of use: Another view Arch Intern Med 154 1994 2531
44. J. Finne M. Leinonen P.J. Mäkelä Antigenic similarities between brain components and bacteria causing meningitis: Implications for vaccine development and pathogenesis Lancet 2 1983 355
45. N. Firgis Y. Sultan Frenk R.W. Jr Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis Ped Infect Dis J 17 1998 816
46. S. Flexner The results of serum treatment in 1300 cases of epidemic meningitis J Exp Med 17 1913 553
47. D.W. Fraser C.C. Geil R.A. Feldman Bacterial meningitis in Bernalillo County, New Mexico: A comparison with three other American populations Am J Epidemiol 100 1997 29
48. M.H. Gaston J.I. Verter G. Woods Prophylaxis with oral penicillin in children with sickle cell anemia N Engl J Med 314 1986 1593
49. G.L. Gilbert S.J. MacInnes I.A. Guise Rifampicin prophylaxis for throat carriage of Haemophilus influenzae type b in patients with invasive disease and their contacts BMJ 302 1991 1432
50. O.H. Gilja A. Halstensen A. Digranes Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis Antimicrob Agents Chemother 7 1993 2024
51. M. Glode Commentary: What price orange urine? Pediatr Infect Dis 1 1982 40
52. R. Gold M.S. Artenstein Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969–1970 Bull World Health Organ 45 1971 279
53. I. Goldschneider E.C. Gotschlich M.S. Artenstein Human immunity to the meningococcus. II. The development of natural immunity J Exp Med 129 1969 1327
54. Gotschlich E.C. Liu T.-Y. M.S. Artenstein Human immunity to the meningococcus. III. Preparation and biochemical properties of the group A, group B and group C meningococcal polysaccharide J Exp Med 129 1969 1349
55. E.D. Gotschlich Development of polysaccharide vaccines for the prevention of meningococcal diseases Monogr Allergy 9 1975 245
56. D.M. Granoff R.K. Gupta R.B. Belshe Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination J Infect Dis 178 1998 870
57. C. Gray Meningococcal disease: Was Ottawa's mass-vaccination program necessary? Can Med Assoc J 146 1992 1033
58. S. Greenfield P.R. Sheehe H.A. Feldman Meningococcal carriage in a population of “normal” families J Infect Dis 23 1971 67
59. A.M. Greenwood B.M. Greenwood A.K. Bradley Enhancement of the immune response to meningococcal polysaccharide vaccine in a malaria endemic area by administration of chloroquine Ann Trop Med Parasitol 75 1981 261
60. R.B. Guttler G.W. Counts C.K. Avent Effect of rifampicin and minocycline on meningococcal carrier rates J Infect Dis 124 1971 199
61. M. Heidelberger C.M. MacLeod Lapi MM di The human antibody response to simultaneous injection of six specific polysaccharides of pneumococci J Exp Med 88 1948 369
62. C.W. Hoge M.R. Reichler E.A. Dominguez An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail N Engl J Med 331 1994 543
63. K. Hoppenbrouers R. Lagos B. Swennen Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DPT) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile Vaccine 16 1998 921
64. S.E. Hume Mass voluntary immunization campaigns form meningococcal disease in Canada: Media hysteria JAMA 267 1992 1833
65. L.A. Jackson A. Schuchat M.W. Reeves Serogroup C meningococcal outbreaks in the United States. An emerging threat JAMA 273 1995 383 389
66. L.A. Jackson A. Schuchat R.D. Gorsky Should college students be vaccinated against meningococcal disease? A cost-benefit analysis Am J Public Health 85 1995 843
67. J.A. Jacobson P.A.M. Camargos J.T. Ferreira The risk of meningitis among classroom contacts during an epidemic of meningococcal disease Am J Epidemiol 104 1976 552
68. Jónsdóttir K. Steingrímsson Ó Ólafsson Ó Immunizaton of infants in Iceland against Haemophilus influenzae type b Lancet 340 1992 252
69. A.B. Kaiser C.H. Hennekens M.S. Saslaw Seroepidemiology and chemoprophylaxis of diseases due to sulfonamide-resistant Neisseria meningitidis in a civilian population J Infect Dis 130 1974 217
70. M. Kauppi J. Eskola H. Käyhty Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines Pediatr Infect Dis J 14 1995 286 294
71. H. Käyhty V. Karanko H. Peltola Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children J Infect Dis 142 1980 861
72. H. Käyhty H. Peltola V. Karanko The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b J Infect Dis 147 1983 1100
73. H. Käyhty H. Peltola J. Eskola Immunogenicity of Haemophilus influenzae oligosaccharide-protein and polysaccharide-protein conjugate vaccination of children at 4, 6, and 14 months of age Pediatrics 84 1989 995 999
74. W.J. King N. MacDonald G. Wells Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children J Pediatr 128 1996 196
75. M. Koskela Antibody response of young children to parenteral vaccination with pneumococcal capsular polysaccharides: A comparison between antibody levels in serum and middle ear effusion Pediatr Infect Dis J 5 1986 431
76. Kristiansen B.-E. Y. Tveten A. Jenkins Which contacts of patients with meningococcal disease carry the pathogenic strain of Neisseria meningitidis ? A population based study BMJ 317 1998 621
77. D.M. Kuhns C.T. Neson H.A. Feldman The prophylactic value of sulfadiazine in the control of meningococcic meningitis JAMA 1234 1943 335
78. R. Lagos M.T. Valenzuela O.S. Levine Economisation of vaccination against Haemophilus influenzae type b: A randomised trial of immunogenicity of fractional-dose and two-dose regimens Lancet 351 1998 1472
79. L. Lapeyssonie La méningite cérébro-spinale en Afrique Bull World Health Organ 28 suppl 1963 1
80. A. Leach P.A. Twumasi S. Kumah Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine J Infect Dis 175 1997 200
81. D. Lennon B. Gellin D. Hood Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand Pediatr Infect Dis J 11 1992 617
82. M. Lepow I. Goldschneider R. Gold Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines Pediatrics 60 1977 673
83. M.R. Lifely C. Moreno Vaccine against meningococcal group B disease Lancet 1 1986 214
84. R conjugated meningococcal C (MenC) vaccine induces immunologic memory while plain Men polysaccharide (PS) vaccine induces tolerance [abstract G-3]. In Programs and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997, p 192
85. C.M. MacLeod R.G. Hodges M. Heidelberger Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides J Exp Med 82 1945 445
86. P.H. Mäkelä H. Peltola H. Käyhty Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: A field trial in Finland J Infect Dis 136 suppl 1977 S43
87. M. Mann H.F. Hull New Haemophilus influenzae type b control strategy: Premature commitment to prophylaxis? Pediatrics 72 1983 118
88. R. Mayon-White Protection for the asplenic patient Prescribers Journal 34 1994 165
89. J.B. McCormick H.H. Gusmao S. Nakamura Antibody response to serogroup A and C meningococcal vaccines in infants born to mothers vaccinated during pregnancy J Clin Invest 65 1980 1141
90. Miller MA, Wenger J, Rosenstein N, et al: Evaluation of meningococcal meningitis control strategies for the Meningitis Belt in Africa [abstract K-127]. In Programs and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997, p 350
91. E.K. Mulholland S. Hilton R.A. Adegbola Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine prevention of pneumonia and meningitis in Gambian infants Lancet 349 1997 1191
92. R.S. Munford A.E. Taunay de Morais J.S. Spread of meningococcal infection within households Lancet 1 1974 1275
93. Nishioka S de A. Effectiveness of BC meningococcal vaccine in Brazil Int J Epidemiol 25 1996 1102
94. C.P. Noronha C.J. Struchiner M.E. Halloran Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: A case-control study Int J Epidemiol 24 1995 1050
95. J.P. Nuorti J.C. Butler J.M. Crutcher An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents N Engl J Med 38 1998 1861
96. M.T. Osterholm T.D. Murphy Does rifampin prophylaxis prevent disease caused by Haemophilus influenzae type b? JAMA 251 1984 2408
97. H. Peltola P.H. Mäkelä H. Käyhty Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age N Engl J Med 297 1977 686
98. H. Peltola Meningococcal disease—still with us Rev Infect Dis (Clinical Infectious Diseases) 5 1982 71
99. H. Peltola M.A. Kataja P.H. Mäkelä Shift in the age-distribution of meningococcal diseases as predictor of an epidemic? Lancet 2 1982 595
100. H. Peltola T. Kilpi M. Anttila Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunization with conjugate vaccines Lancet 340 1992 592
101. H. Peltola Vaccines Against Bacterial Meningitis Scheld W.M. Whitley R.J. Durack D.T. Infections of the Central Nervous System ed 2 1997 Lippincott-Raven Publishers Philadelphia, PA 1013
102. H. Peltola Meningococcal vaccines. Current status and future possibilities Drugs 55 1998 347
103. H. Peltola M.A. Kataja P.H. Mäelä Shift in the age-distribution of meningococcal diseases as predictor of an epidemic? Lancet 2 1982 595
104. 135) meningococcal vaccines in infants and small children. A clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides Pediatrics 76 1985 91
105. H. Peltoa M. Anttila Renkonen O.-V. Randomised comparison of chloramphenicol, ampicillin, cefotaxime and ceftriaxone for childhood bacterial meningitis Lancet 1 1989 1281
106. H. Peltola P. Aavitsland K.G. Hansen Perspective: A five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia J Infect Dis 179 1999 223
107. H. Peltola Haemophilus influenzae type b disease and vaccination in Latin America and The Caribbean Pediatr Infect Dis J 16 1997 780
108. B.A. Perkins K. Jonsdottir H. Briem Immunogenicity of two efficaceous outer membrane protein-based serogroup B meningococcal vaccines among adults in Iceland J Infect Dis 177 1998 683
109. D.C. Powers E.L. Anderson K. Lottenbach Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults J Infect Dis 173 1996 1014
110. P.M. Pugsley D.L. Dworzack E.A. Horowitz Efficiency of ciprofloxacin in the treatment of nasopharyngeal carriers of Neisseria meningitidis J Infect Dis 156 1987 211
111. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Prevention of pneumococcal disease MMWR Morb Mortal Wkly Rep 46 1997 RR-8
112. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Control and prevention of meningococcal disease, and control and prevention of serogroup C meningococcal disease: Evaluation and management of suspected outbreaks MMWR Morb Mortal Wkly Rep 46 RR-5 1997 1
113. A.L. Reingold C.V. Broome A.W. Hightower Age-specific differences in duration of clinical protection after vaccinations with meningococcal polysaccharide A vaccine Lancet 2 1985 114
114. O.V. Renkonen A. Sivonen R. Visakorpi Effect of ciprofloxacin on carrier rate of Neisseria meningitidis in army recruits of Finland Antimicrob Agents Chemother 31 1987 962
115. N. Rosenstein O. Levine J.P. Taylor Efficacy of meningococcal vaccine and barriers to vaccination JAMA 279 1998 435
116. X. Sáez-Llorens M.S. Ah-Chu E. Castaño Intrapartum prophylaxis ith ceftriaxone decreases rates of bacterial colonization and early-onset infection in newborns Clin Infect Dis 21 1885 876
117. I. Salmi O. Pettay I. Simola An epidemic due to sulphonamide-resistant group A meningococci in the Helsinki area (Finland). Epidemiological and clinical observations Scand J Infect Dis 8 1976 249
118. U. Sankilampi P.O. Honkanen A. Bloigu Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly J Infect Dis 176 1997 1100
119. M. Santosham M. Wolff R. Reid The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex N Engl J Med 324 1991 1767
120. B. Schwartz A. Al-Ruwais A'ashi Jalal Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A Neisseria meningitidis Lancet 1 1988 1239
121. F. Shann Pneumococcal vaccine: Time for another controlled trial Lancet 351 1998 1600
122. E.D. Shapiro A.T. Berg R. Austrian The protective efficacy of polyvalent pneumococcal polysaccharide vaccine N Engl J Med 325 1991 1453
123. G.V.G. Sierra H.C. Capa N.M. Varcacel Vaccine against group B Neisseria meningitidis : Protection trial and mass vaccination results in Cuba National Institute for Public Health (Oslo, Norway) Annals 14 1991 195
124. A.K. Takala J. Eskola J. Palmgren Risk factors of invasive Haemophilus influenzae type b disease among children in Finland J Pediatr 115 1989 694
125. A.D. Takala J. Eskola M. Leinonen Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine J Infect Dis 164 1991 982
126. J.W. Tappero R. Lagos Maldonoado Ballesteros A. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomized controlled study in Chile JAMA 281 1999 1520
127. A.E. Taunay R.A. Feldman C.O. Bastos Avaliaçao do efeito protetor de vacina polissacaridica antimeningocócica do grupo C, em crianças de 6 a 36 meses Rev Instituto Adolfo Lutz (São Paulo, Brazil) 38 1978 82 77
128. The Meningococcal Disease Surveillance Group Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis J Infect Dis 134 1976 201
129. D.C. Turk Naso-pharyngeal carriage of Haemophilus influenzae type b Journal of Hygeine (Lond) 61 1963 247
130. C.M. Vadheim D.P. Greenberg E. Eriksen Eradication of Haemophilus influenzae type b disease in Southern California Arch Pediatr Adolesc Med 148 1994 51
131. M.H. Wahdan F. Rizk el-Akkad A.M. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine Bull World Health Organ 48 1973 667
132. J.I. Ward D.W. Fraser L.J. Baraff Haemophilus influenzae meningitis: A national study of secondary spread in household contacts N Engl J Med 301 1979 122
133. J. Ward G. Brenneman G.W. Letson Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaskan native infants N Engl J Med 323 1990 1393
134. J.D. Wenger A.W. Hightower R.R. Facklam Bacterial meningitis in the United States, 1986: Report of a multistate study J Infect Dis 162 1990 1316
135. Whitney CG, Dondoc N, Enktuja B, et al: Control of epidemic serogroup A meningococcal disease, Mongolia [poster 20.011]. In Programs and Abstracts of the 7th International Congress for Infectious Diseases, Hong Kong, 1996, p 42
136. WHO, Fondation Marcel Mérieux: Control of epidemic meningococcal disease. WHO Practical Guidelines. Edition Fondation Marcel Mérieux, Lyon, France, 1995, ESBN 2-84039-037-X
137. Wright A.E. Parry Morgan W. M.B. Cantab Observations on prophylactic inoculation against pneumococcus infections, and on the results achieved by it Lancet 1 1914 1
138. K.M. Zangwill A. Schuchat F.X. Riedo School-based clusters of meningococcal disease in the United States: Descriptive epidemiology and a case-control analysis JAMA 227 1997 389
139. W.D. Zollinger J. Boslego E. Moran Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile National Institute for Public Health (Oslo, Norway) Annals 14 1991 211
140. P. Yagupsky S. Ashkenazi C. Block Rifampicin-resistant meningococci causing invasive disease and failure of chemoprophylaxis Lancet 341 1993 1152